Connection

Laurent Peyrin-Biroulet to Colitis, Ulcerative

Back to Details
This is a "connection" page, showing publications Laurent Peyrin-Biroulet has written about Colitis, Ulcerative.
Laurent Peyrin-Biroulet
Connection Strength
8.604
Colitis, Ulcerative
  1. Will COVID-19 Infection be Less Severe in Ulcerative Colitis Than in Crohn's Patients, Due to a Lower Rate of Smokers? J Crohns Colitis. 2020 Nov 07; 14(11):1648.
    View in: PubMed
    Score: 0.428
  2. Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies. Autoimmun Rev. 2019 Feb; 18(2):123-128.
    View in: PubMed
    Score: 0.376
  3. Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. Dig Liver Dis. 2019 03; 51(3):327-334.
    View in: PubMed
    Score: 0.374
  4. Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational study. Dig Liver Dis. 2019 02; 51(2):236-241.
    View in: PubMed
    Score: 0.373
  5. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. Inflamm Bowel Dis. 2018 09 15; 24(10):2106-2112.
    View in: PubMed
    Score: 0.369
  6. Integrating Patient-Reported Outcomes Into Treat-to-Target Monitoring Algorithms. Clin Gastroenterol Hepatol. 2019 02; 17(3):395-396.
    View in: PubMed
    Score: 0.368
  7. Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach. Dig Dis. 2018; 36(5):346-353.
    View in: PubMed
    Score: 0.364
  8. Diffusion-weighted MRI in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2018 06; 3(6):433-443.
    View in: PubMed
    Score: 0.362
  9. Colorectal cancer prevention in patients with ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:103-109.
    View in: PubMed
    Score: 0.361
  10. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:17-25.
    View in: PubMed
    Score: 0.361
  11. Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation. Gut. 2019 01; 68(1):178-179.
    View in: PubMed
    Score: 0.352
  12. Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting. J Dig Dis. 2017 Oct; 18(10):566-573.
    View in: PubMed
    Score: 0.346
  13. Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Rev Clin Pharmacol. 2017 Dec; 10(12):1363-1374.
    View in: PubMed
    Score: 0.345
  14. Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile. J Crohns Colitis. 2017 Jul 01; 11(7):767-768.
    View in: PubMed
    Score: 0.340
  15. Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study. Dig Liver Dis. 2017 Mar; 49(3):280-285.
    View in: PubMed
    Score: 0.327
  16. Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn's and Colitis Organization. Gastroenterology. 2020 Jul; 159(1):14-19.e3.
    View in: PubMed
    Score: 0.103
  17. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. Br J Clin Pharmacol. 2019 10; 85(10):2244-2254.
    View in: PubMed
    Score: 0.098
  18. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. Gastroenterology. 2019 09; 157(3):647-659.e4.
    View in: PubMed
    Score: 0.096
  19. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. Immunotherapy. 2019 05; 11(7):565-575.
    View in: PubMed
    Score: 0.095
  20. Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. Dig Dis. 2019; 37(4):266-283.
    View in: PubMed
    Score: 0.095
  21. Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. J Crohns Colitis. 2018 Nov 28; 12(12):1385-1391.
    View in: PubMed
    Score: 0.094
  22. Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. Clin Gastroenterol Hepatol. 2019 08; 17(9):1673-1679.e1.
    View in: PubMed
    Score: 0.093
  23. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. Inflamm Bowel Dis. 2018 10 12; 24(11):2442-2451.
    View in: PubMed
    Score: 0.093
  24. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 02; 17(3):494-501.
    View in: PubMed
    Score: 0.092
  25. Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. Gut. 2019 07; 68(7):1162-1168.
    View in: PubMed
    Score: 0.092
  26. PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. Expert Opin Investig Drugs. 2018 Jul; 27(7):623-629.
    View in: PubMed
    Score: 0.091
  27. Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. Dig Liver Dis. 2018 10; 50(10):1019-1029.
    View in: PubMed
    Score: 0.091
  28. Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses. Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:43-47.
    View in: PubMed
    Score: 0.091
  29. Post-operative complications in elderly onset inflammatory bowel disease: a population-based study. Aliment Pharmacol Ther. 2018 06; 47(12):1652-1660.
    View in: PubMed
    Score: 0.090
  30. Zinc-Alpha-2-Glycoprotein in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 04 23; 24(5):e10.
    View in: PubMed
    Score: 0.090
  31. Impact of age at diagnosis on natural history of patients with elderly-onset ulcerative colitis: A French population-based study. Dig Liver Dis. 2018 Sep; 50(9):903-909.
    View in: PubMed
    Score: 0.090
  32. Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply. Aliment Pharmacol Ther. 2018 02; 47(4):540-541.
    View in: PubMed
    Score: 0.088
  33. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018 02; 47(4):454-465.
    View in: PubMed
    Score: 0.087
  34. Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther. 2018 01; 47(2):219-228.
    View in: PubMed
    Score: 0.087
  35. Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab-treated patients. Aliment Pharmacol Ther. 2017 11; 46(10):1019-1020.
    View in: PubMed
    Score: 0.087
  36. Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study. J Crohns Colitis. 2017 Oct 27; 11(11):1326-1334.
    View in: PubMed
    Score: 0.087
  37. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. J Crohns Colitis. 2017 Oct 27; 11(11):1317-1325.
    View in: PubMed
    Score: 0.087
  38. Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index. Aliment Pharmacol Ther. 2018 Jan; 47(1):6-15.
    View in: PubMed
    Score: 0.087
  39. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clin Gastroenterol Hepatol. 2018 05; 16(5):637-647.e13.
    View in: PubMed
    Score: 0.086
  40. Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988-2011): A Population-Based Study of French Adolescents. Am J Gastroenterol. 2018 02; 113(2):265-272.
    View in: PubMed
    Score: 0.086
  41. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Dig Liver Dis. 2017 Oct; 49(10):1086-1091.
    View in: PubMed
    Score: 0.085
  42. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017 08; 46(3):310-321.
    View in: PubMed
    Score: 0.085
  43. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017 May; 45(10):1291-1302.
    View in: PubMed
    Score: 0.083
  44. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017 05; 45(9):1179-1192.
    View in: PubMed
    Score: 0.083
  45. IBD immunopathogenesis: A comprehensive review of inflammatory molecules. Autoimmun Rev. 2017 Apr; 16(4):416-426.
    View in: PubMed
    Score: 0.083
  46. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther. 2017 Mar; 45(6):801-813.
    View in: PubMed
    Score: 0.082
  47. The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. Clin Gastroenterol Hepatol. 2016 09; 14(9):e121-2.
    View in: PubMed
    Score: 0.080
  48. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut. 2017 04; 66(4):588-596.
    View in: PubMed
    Score: 0.076
  49. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut. 2013 Dec; 62(12):1714-23.
    View in: PubMed
    Score: 0.062
  50. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut. 2012 Jan; 61(1):78-85.
    View in: PubMed
    Score: 0.057
  51. Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. Gut Microbes. 2019; 10(2):149-158.
    View in: PubMed
    Score: 0.023
  52. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2018 02; 47(4):485-493.
    View in: PubMed
    Score: 0.022
  53. Frequency of and Factors Associated With Sexual Dysfunction in Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2017 Oct 27; 11(11):1347-1352.
    View in: PubMed
    Score: 0.022
  54. Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer-authors' reply. Aliment Pharmacol Ther. 2017 06; 45(12):1554-1555.
    View in: PubMed
    Score: 0.021
  55. Incidence and Phenotype at Diagnosis of Very-early-onset Compared with Later-onset Paediatric Inflammatory Bowel Disease: A Population-based Study [1988-2011]. J Crohns Colitis. 2017 May 01; 11(5):519-526.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.